Legal advisor to the management of Julius Clinical on sale to Ampersand Capital Partners
Acted as legal advisor to the management of Julius Clinical Research in connection with the sale to Ampersand Capital Partners.
Julius Clinical is a contract research organization active in clinical research. The investment by Ampersand Capital Partners was intended to support further growth and international expansion, including in Europe and North America. Dealmaker lists the transaction as “Ampersand Capital Partners acquires Julius Clinical”, with a EUR 25–50 million transaction value category and a transaction date of 23 November 2023.
The legal work focused on the management position in the transaction, sale documentation, management participation and arrangements with the new investor. In private equity transactions involving management, the sale, reinvestment, governance and future management position need to be carefully aligned.
Need legal advice on a private equity transaction or management participation?
For questions about management participation, reinvestment, shareholder documentation or private equity transactions, please contact dirk.dewaard@viottalaw.com.
Deal highlights
Transaction type – Sale / private equity transaction / management participation
Client – Management of Julius Clinical Research
Buyer – Ampersand Capital Partners
Sector – Life sciences / clinical research / CRO
Role – Legal advisor to management
Legal work – Transaction documentation, management position, reinvestment, governance and private equity arrangements
Links
Dealmaker — Ampersand Capital Partners acquires Julius Clinical
Julius Clinical press release
PR Newswire
Related expertise
Private equity
Corporate / M&A
Shareholders agreement
Investment agreement
Commercial contracts
